Commitment to Fight COVID-19
As of April 21th, 2021
News
About Shionogi
Shionogi is fully committed to achieving the goals of SGS2020 and ensuring that the Group continues to grow after 2020, while also realizing our corporate mission globally: “To strive constantly to supply the best possible medicine to protect the health and wellbeing of the patients we serve.”
Investors
Shionogi’s Disclosure Policy states that as a company trusted widely by society, the Company recognizes that management transparency is one of its most important responsibilities. Based on this recognition, the Company discloses information to all stakeholders in a fair, timely, appropriate and continuous manner.
Innovation
Supported by our world-class SAR engine for small molecule drug discovery, which allows us to efficiently create innovative small-molecule pharmaceuticals, we have successfully launched a stream of competitive, ground-breaking new drugs. If we are to meet the needs of both our customers and society as a whole and become a source of new value in the healthcare fi eld, we think it essential that Shionogi remain committed to innovation, particularly as it applies to R&D.
Sustainability
Shionogi aims to “grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improved healthcare.” To do this, we need to devote energy to achieving constant innovation and at the same time fulfill its duty as a public entity by taking account of social needs. By building a solid business foundation able to respond flexibly to changes in the environment, we are taking action to position Shionogi as a company whose future continuation is important to all stakeholders.
